Evidence map›Paper›PMID 40374814›Full record

ArticleScientific reports2025

CT-Derived spleen volume accurately diagnoses severe portal hypertension at HVPG thresholds of 16 mmhg.

Xinyu Chen, Jiamei Zhou, Yicheng Lin, Kefeng Jia, Jiajun Tian, Fenghui Li, Rong Lv, Weili Yin, Fang Wang, Ping Zhu and 7 more

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. [Non-invasive evaluation and prediction of portal hypertension: focusing on disease progression and outcome].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2025
    Review
  7. Journal of clinical and experimental hepatology
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Xinyu Chen *The Third Central Clinical College of Tianjin Medical University, Tianjin University Central Hospital (Tianjin Third Central Hospital), Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases, Institute of Hepatobiliary Disease, Tianjin, China.
Jiamei Zhou *Tianjin Union Medical Center, Tianjin Medical University, Tianjin, China.
Yicheng Lin *The Third Central Clinical College of Tianjin Medical University, Tianjin University Central Hospital (Tianjin Third Central Hospital), Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases, Institute of Hepatobiliary Disease, Tianjin, China.
Kefeng Jia *Tianjin University Central Hospital(Tianjin Third Central Hospital), Department of Gastroenterology and Hepatology, Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases, Institute of Hepatobiliary Disease, No 83, Jintang road, Hedong district, Tianjin, China.
Jiajun Tian *Tianjin University Central Hospital(Tianjin Third Central Hospital), Department of Gastroenterology and Hepatology, Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases, Institute of Hepatobiliary Disease, No 83, Jintang road, Hedong district, Tianjin, China.
Fenghui Li *Tianjin University Central Hospital(Tianjin Third Central Hospital), Department of Gastroenterology and Hepatology, Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases, Institute of Hepatobiliary Disease, No 83, Jintang road, Hedong district, Tianjin, China.
Rong LvTianjin University Central Hospital(Tianjin Third Central Hospital), Department of Gastroenterology and Hepatology, Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases, Institute of Hepatobiliary Disease, No 83, Jintang road, Hedong district, Tianjin, China.
Weili YinTianjin University Central Hospital(Tianjin Third Central Hospital), Department of Gastroenterology and Hepatology, Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases, Institute of Hepatobiliary Disease, No 83, Jintang road, Hedong district, Tianjin, China.
Fang WangTianjin University Central Hospital(Tianjin Third Central Hospital), Department of Gastroenterology and Hepatology, Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases, Institute of Hepatobiliary Disease, No 83, Jintang road, Hedong district, Tianjin, China.
Ping ZhuTianjin University Central Hospital(Tianjin Third Central Hospital), Department of Gastroenterology and Hepatology, Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases, Institute of Hepatobiliary Disease, No 83, Jintang road, Hedong district, Tianjin, China.
Chao YangTianjin University Central Hospital(Tianjin Third Central Hospital), Department of Gastroenterology and Hepatology, Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases, Institute of Hepatobiliary Disease, No 83, Jintang road, Hedong district, Tianjin, China.
Jiayin WangTianjin University Central Hospital(Tianjin Third Central Hospital), Department of Gastroenterology and Hepatology, Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases, Institute of Hepatobiliary Disease, No 83, Jintang road, Hedong district, Tianjin, China.
Tao WangTianjin University Central Hospital(Tianjin Third Central Hospital), Department of Gastroenterology and Hepatology, Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases, Institute of Hepatobiliary Disease, No 83, Jintang road, Hedong district, Tianjin, China.
Junqing YanTianjin University Central Hospital(Tianjin Third Central Hospital), Department of Gastroenterology and Hepatology, Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases, Institute of Hepatobiliary Disease, No 83, Jintang road, Hedong district, Tianjin, China.
Ying LiuTianjin University Central Hospital(Tianjin Third Central Hospital), Department of Gastroenterology and Hepatology, Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases, Institute of Hepatobiliary Disease, No 83, Jintang road, Hedong district, Tianjin, China.
Qing YeTianjin University Central Hospital(Tianjin Third Central Hospital), Department of Gastroenterology and Hepatology, Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases, Institute of Hepatobiliary Disease, No 83, Jintang road, Hedong district, Tianjin, China. yeqing022@163.com.
Huiling XiangTianjin University Central Hospital(Tianjin Third Central Hospital), Department of Gastroenterology and Hepatology, Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases, Institute of Hepatobiliary Disease, No 83, Jintang road, Hedong district, Tianjin, China. huilingxiang@163.com.

Funding

Funded by Tianjin Key Medical Discipline (Specialty)Construction Project TJYXZDXK-034ASponsored by Tianjin Health Research Project. No. TJWJ2022XK029
6 · The paper itself

Abstract

To investigate the diagnostic utility of a noninvasive method based on spleen volume for the accurate diagnosis of severe portal hypertension (PH). We enrolled 260 patients undergoing hepatic venous pressure gradient (HVPG) assessment and enhanced CT at Tianjin Third Central Hospital (December 2019-July 2023), with clinical data collected. Patients were stratified by HVPG levels: ≥16 mmHg (severe PH group) and < 16 mmHg (non-severe PH group). We included 120 cirrhotic patients who met the inclusion criteria. Splenic volume exhibited a linear correlation with HVPG (r = 0.364, p < 0.001). Univariate and multivariate logistic regression analyses identified spleen volume, age, and serum albumin as independent risk factors for severe PH (p < 0.05). Accordingly, a clinical diagnostic model was developed, named the "S-HVPG" score. The area under the curve (AUC) for the "S-HVPG" score was 0.803, with an optimal threshold of 0.694, achieving sensitivity, specificity, positive predictive value(PPV), and negative predictive value (NPV) of 78.8%, 74.3%, 88.2%, and 59.1%, respectively. The spleen volume-based "S-HVPG" scoring system introduces a novel, straightforward, noninvasive approach for diagnosing severe PH. A cutoff value of 0.694 for the S-HVPG score effectively distinguishes patients with severe PH from those with cirrhosis.

Indexed as

Hypertension, PortalPortal PressureSpleenTomography, X-Ray ComputedAdultAgedFemaleHumansLiver CirrhosisMaleMiddle AgedOrgan SizeRetrospective StudiesCirrhosisDiagnostic modelHepatic venous pressure gradientPortal hypertensionSpleen volume

Identifiers

PMID40374814
PMCPMC12081866

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.